| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jen-Hung Huang, Yao-Chang Chen, Ting-I Lee, Yu-Hsun Kao, Tze-Fan Chazo, Shih-Ann Chen, Yi-Jen Che. Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes. Peptides. vol 78. 2016-12-13. PMID:26930508. |
administration of glp-1 provides cardioprotective effects through attenuating cardiac inflammation and insulin resistance. |
2016-12-13 |
2023-08-13 |
Not clear |
| Michelle H Johnson, Elvira Gonzalez de Meji. Phenolic Compounds from Fermented Berry Beverages Modulated Gene and Protein Expression To Increase Insulin Secretion from Pancreatic β-Cells in Vitro. Journal of agricultural and food chemistry. vol 64. issue 12. 2016-12-13. PMID:26967923. |
the objectives were to determine the role of berry phenolic compounds to modulate incretin-cleaving dpp-iv and its substrate glucagon-like peptide-1 (glp-1), insulin secretion from pancreatic β-cells, and genes and proteins involved in the insulin secretion pathway using cell culture. |
2016-12-13 |
2023-08-13 |
Not clear |
| Michelle H Johnson, Elvira Gonzalez de Meji. Phenolic Compounds from Fermented Berry Beverages Modulated Gene and Protein Expression To Increase Insulin Secretion from Pancreatic β-Cells in Vitro. Journal of agricultural and food chemistry. vol 64. issue 12. 2016-12-13. PMID:26967923. |
anc 50%blu-bla and anc 100%bla upregulated the gene for incretin hormone glp-1 (fold-change 3.0 ± 1.4 and 2.0 ± 0.3, respectively) and genes in the insulin secretory pathway including insulin-like growth factor 1 receptor (igf1r, 2.3 ± 0.6 and 1.6 ± 0.3, respectively), and increased (p < 0.05) the protein expression of insulin-like growth factor 2 (igf-ii), insulin-like growth factor binding proteins (igfbp-2 and 3), and vascular endothelial growth factor (vegf) in ins-1e cells. |
2016-12-13 |
2023-08-13 |
Not clear |
| Michelle H Johnson, Elvira Gonzalez de Meji. Phenolic Compounds from Fermented Berry Beverages Modulated Gene and Protein Expression To Increase Insulin Secretion from Pancreatic β-Cells in Vitro. Journal of agricultural and food chemistry. vol 64. issue 12. 2016-12-13. PMID:26967923. |
taken together, anthocyanins, predominantly delphinidin-3-arabinoside, from fermented berry beverages have the potential to modulate dpp-iv and its substrate glp-1, to increase insulin secretion, and to upregulate expression of mrna of insulin-receptor associated genes and proteins in pancreatic β-cells. |
2016-12-13 |
2023-08-13 |
Not clear |
| Pr Bernard Charbonne. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774014. |
basal insulin intensification in type 2 diabetes: a key role for glp-1 receptor agonists. |
2016-11-11 |
2023-08-13 |
Not clear |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
glp-1 ras as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4b and get-goal duo 2 trials. |
2016-11-11 |
2023-08-13 |
human |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
the add-on of a prandial (short-acting) glp-1 ra to basal insulin in subjects with t2dm who fail to control a1c on basal insulin, stems from the physiological principles of post-prandial glucose homeostasis, and it is based on evidence from clinical trials. |
2016-11-11 |
2023-08-13 |
human |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
the 4b and getgoal duo 2 studies are the first to establish in head-to-head comparison, the efficacy and safety of short-acting glp-1 ras vs prandial insulin, when added-on to basal insulin glargine. |
2016-11-11 |
2023-08-13 |
human |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
in both studies a similar percentage of subjects reached the a1c <7.0% on glp-1 ra or prandial insulin. |
2016-11-11 |
2023-08-13 |
human |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
the studies 4b and getgoal duo 2 suggest that after failure of basal insulin in t2dm, the add-on of prandial glp-1 ra is as effective as prandial insulin in lowering a1c, with added benefits of reducing body weight and risk for hypoglycemia. |
2016-11-11 |
2023-08-13 |
human |
| F Porcellati, P Lucidi, G B Bolli, C G Fanell. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774015. |
in addition, the glp-1 ra + basal insulin is a simpler therapeutic option as compared to basal-plus and basal-bolus regimens. |
2016-11-11 |
2023-08-13 |
human |
| P Darmon, D Racca. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists? Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774016. |
options for intensification of basal insulin in type 2 diabetes: premeal insulin or short-acting glp-1 receptor agonists? |
2016-11-11 |
2023-08-13 |
Not clear |
| P Darmon, D Racca. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists? Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774016. |
as for glp-1 ras, numerous studies, and especially those using short-acting glp-1 ras, have demonstrated more pronounced effects on postprandial hyperglycaemia, good complementary effects with basal insulin, and significant improvement of hba1c with no weight gain and a low risk of hypoglycaemia. |
2016-11-11 |
2023-08-13 |
Not clear |
| P Darmon, D Racca. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists? Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774016. |
similarly, direct and indirect comparisons of the use of rapid-acting insulins and glp-1 ras to intensify basal insulin have shown comparable efficacy in terms of hba1c control, but with less weight gain and fewer hypoglycaemic episodes with glp-1 ras. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Cario. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774017. |
pleiotropic effects of insulin and glp-1 receptor agonists: potential benefits of the association. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Ahré. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774018. |
physiological aspects of the combination of insulin and glp-1 in the regulation of blood glucose control. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Ahré. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774018. |
combining insulin with glucagon-like peptide-1 (glp-1) receptor agonists or dipeptidyl peptidase-4 (dpp-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over the past few years. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Ahré. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774018. |
one advantage of this combination is the complementary mechanistic actions of insulin and glp-1. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Ahré. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774018. |
on the other hand, glp-1 stimulates insulin secretion, inhibits glucagon secretion and retards gastric emptying. |
2016-11-11 |
2023-08-13 |
Not clear |
| B Ahré. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & metabolism. vol 41. issue 6 Suppl 1. 2016-11-11. PMID:26774018. |
in addition, glp-1 receptor agonists induce satiety, leading to decreases in food intakes and body weight, thereby preventing the weight gain often seen with insulin therapy. |
2016-11-11 |
2023-08-13 |
Not clear |